TCRX

Tscan Therapeutics
$0.20
−$0.00 (−2.01%)Oct 29, 2026
1.8PoorMoatMint rating

MoatMint rates Tscan Therapeutics (TCRX) 1.8 out of 10, a research rating of the company's quality, value, growth, momentum and financial health. Its quality rating is 2.4 out of 10.

Return-97.7%5YRange $0.19 - $8.98
$10.0$6.7$3.3$0.0Nov 21Sep 25Oct 26

Key metrics

The numbers that frame TCRX today
Market cap
$13.22M
Gross margin
100%
ROIC
-80.9%
Div yield
0%
Debt / equity
1.3
52wk Low
$0.18
52wk High
$2.14

TCRX stock rating

How TCRX scores on quality, value, growth, momentum and financial health
1.8out of 10
Low overallNeutral business, valuation unclear
Quality2.4
Growth8.2
Momentum0.5
Value-
Financial Health0.7

Growth

Revenue and earnings trend for TCRX
RevenueNet income
See the full growth breakdown

Revenue and earnings trends, margins and the multi-year trajectory - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Cash flow & returns

Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture

Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Insider trading

Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade

See who is buying and selling, how much, and when - updated as new filings land.

Create a free account
Free foreverNo card required
Already a member? Log in

Frequently asked questions

Plain-English answers about TCRX
Is Tscan Therapeutics a good buy?
No. Tscan Therapeutics has poor quality and poor momentum. Both signals point to a weaker setup. Growth looks excellent, which supports the long-term business case, but that is not enough to offset the weak setup.
What is the market capitalization of TCRX?
Tscan Therapeutics's market capitalization is $13.22M.
What is the 52-week high for TCRX stock?
The 52-week high for Tscan Therapeutics is $2.14. The current close of $0.20 is 90.9% below that high.
What is the 52-week low for TCRX stock?
The 52-week low for Tscan Therapeutics is $0.18. The current close of $0.20 is 8.3% above that low.
Does TCRX stock pay dividends?
Tscan Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for TCRX?
Tscan Therapeutics's Debt / Equity ratio is 1.32.